Tremeau Pharmaceuticals, Inc.
Non-opioid pain therapy pharmaceuticals
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2016
- Latest Form D
- $5.2M, Feb 2018
- Total capital
- $5.2M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $5.2M
- 1 Form D · last Feb 2018
- 104 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 8
- 24 pending · first 2021
- Rank in peer group#196 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$5.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#196 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Bradford C. SippyResearcherExecutive Officer, DirectorLinked by 3 patents
- Benjamin C. EnersonExecutive OfficerNamed in SEC Form D filings
- Mark C. CorriganExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 8 granted of 32- GrantedPurified Forms Of Rofecoxib, Methods Of Manufacture And UseUSPTOUS 11,872,206
- GrantedDeuterated Etoricoxib, Methods Of Manufacture, And Use ThereofUSPTOUS 11,858,909
- GrantedPurified Forms Of Rofecoxib, Methods Of Manufacture And UseUSPTOUS 11,617,735
Show all 32 patent records
- Purified Forms Of Rofecoxib, Methods Of Manufacture And UseJan 16, 2024 · US 11,872,206Granted
- Deuterated Etoricoxib, Methods Of Manufacture, And Use ThereofJan 2, 2024 · US 11,858,909Granted
- Purified Forms Of Rofecoxib, Methods Of Manufacture And UseApr 4, 2023 · US 11,617,735Granted
- Purified Forms Of Rofecoxib, Methods Of Manufacture And UseFeb 14, 2023 · US 11,576,890Granted
- Purified Forms Of Rofecoxib, Methods Of Manufacture And UseJan 24, 2023 · US 11,559,509Granted
- Dosage Forms Of Rofecoxib And Related MethodsDec 29, 2022 · Application 17855604Pending
- Treatment Of Viral Hemorrhagic Fevers With EtoricoxibSep 1, 2022 · Application 17492359Pending
- Aqueous Formulations Of Water Insoluble COX-2 InhibitorsApr 28, 2022 · Application 17512268Pending
- Novel Dosage Forms Of Rofecoxib And Related MethodsFeb 17, 2022 · Application 17513281Pending
- Deuterated Etoricoxib, Methods Of Manufacture, And Use ThereofNov 2, 2021 · US 11,161,833Granted
- Ingestible Product and a Method of Using the SameAug 12, 2021 · Application 17242759Pending
- Novel Dosage Forms Of Rofecoxib And Related MethodsJun 10, 2021 · Application 17182728Pending
- Novel Dosage Forms Of Rofecoxib And Related MethodsMay 13, 2021 · Application 17127970Pending
- Purified Forms Of Rofecoxib, Methods Of Manufacture And UseApr 27, 2021 · US 10,987,337Granted
- Novel Dosage Forms Of Rofecoxib And Related MethodsMar 16, 2021 · US 10,945,992Granted
- Treatment Of Viral Hemorrhagic Fevers With EtoricoxibOct 15, 2020 · Application 16843808Pending
- Treatment Of Viral Hemorrhagic Fevers With COX-2 Selective Non-steroidal Anti-inflammatory DrugsOct 15, 2020 · Application 16843497Pending
- Ingestible Product And A Method Of Using The SameMar 21, 2019 · Application 16138564Pending
- Aqueous Formulations Of Water Insoluble COX-2 InhibitorsApplication 63106571Pending
- Novel Dosage Forms Of Rofecoxib And Related MethodsApplication PCTUS2020060152Pending
- Novel Dosage Forms of Rofecoxib and Related MethodsApplication 63018136Pending
- Treatment Of Viral Hemorrhagic Fevers With EtoricoxibApplication PCTUS2020027294Pending
- Deuterated Etoricoxib, Methods Of Manufacture, And Use ThereofApplication 63173291Pending
- Treatment Of Viral Hemorrhagic Fevers With COX-2 Selective Non-steroidal Antiinflammatory DrugsApplication PCTUS2020027244Pending
- Methods And Compositions For Treating Von Willebrand's Migraine DisorderApplication 63252842Pending
- Aqueous Formulations Of Water Insoluble COX-2 InhibitorsApplication PCTUS2021056878Pending
- Purified Forms Of Rofecoxib, Methods Of Manufacture And UseApplication PCTUS2019061178Pending
- Novel Dosage Forms Of Rofecoxib And Related MethodsApplication 62934898Pending
- Treatment Of Viral Hemorrhagic Fevers With COX-2 Selective Non-steroidal Anti-inflammatory DrugsApplication 62831407Pending
- Highly Pure Rofecoxib, Methods Of Manufacture And UseApplication 62770563Pending
- An Ingestible Product And A Method Of Using The SameApplication PCTUS2018052225Pending
- Methods And Compositions For Treating Von Willebrand's Migraine DisorderApplication PCTUS2022045753Pending
Related companies, and why
- Viracta Subsidiary, Inc.Similar federal contract value in Biotech · null in contracts
- ReproNovoSimilar federal contract value in Biotech · null in contracts
- Glycologix, LLCSimilar federal contract value in Biotech · null in contracts
- Arbor Assets IncSimilar federal contract value in Biotech · null in contracts
- Prothena Corp plcSimilar federal contract value in Biotech · null in contracts
- EXAVIR THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .